Considered the founder of the biotechnology industry, Genentech has been delivering on the promise of biotechnology for more than 30 years, using human genetic information to discover, develop, manufacture and commercialize biotherapeutics that address significant unmet medical needs. Today, Genentech is among the world’s leading biotech companies, with multiple products on the market for serious or life-threatening medical conditions, more than 100 projects in the pipeline and a long term plan for growth.

Milestones
edit

Genentech added Dan McCall as Mobile Apps Product Manager.

Posted 8/26/11 at 6:38am
Genentech added Louis Bock as Research Associate. (11/1/87)

Posted 12/15/09 at 1:40pm
Genentech added David Ebersman as CFO.

Posted 6/29/09 at 11:18am
Genentech added Arthur D. Levinson as Chairman and CEO.

Posted 3/21/08 at 9:50am
Genentech invested in Constellation Pharmaceuticals. (1/17/12)

Posted 1/17/12 at 5:42am via masshightech.com
Genentech invested in 23andMe. (5/1/07)

Posted 10/15/07 at 9:17am via 23andme.com
Went public with stock symbol DNA.

Posted 12/10/08 at 11:05am